Drug class profile · refreshed daily from federal data

Phosphate Binder

3 molecules in this class, $645.2M combined CY2024 Part D spend across 1.0M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Phosphate Binder class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class
3tracked in Part D
CY24 Part D spend
$645.2Mcombined across class
Total Rx claims
1.0M271K unique beneficiaries
Generic mfrs (active)
21across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard
01
Sucroferric Oxyhydroxide
Brand: Velphoro · 157K Part D claims (CY24) · 39K beneficiaries · First FDA approval:
Brand-only (no generics)
Low NADAC$17.11
Avg plan cost$17.11
Part D spend $439.3M spread, current vs floor
Class share
68%
of class CY24 spend
View profile →
02
Sevelamer Carbonate
Brand: Renvela · 815K Part D claims (CY24) · 220K beneficiaries · First FDA approval:
16 generic mfrs
Low NADAC$0.228
Avg plan cost$1.14
Part D spend $181.9M spread, current vs floor
Class share
28%
of class CY24 spend
View profile →
03
Sevelamer
38K Part D claims (CY24) · 13K beneficiaries · First FDA approval:
5 generic mfrs
Low NADAC$0.745
Avg plan cost$0.948
Part D spend $24.0M spread, current vs floor
Class share
4%
of class CY24 spend
View profile →